| 50.96 Delayed Data As of Jun 14 |  -0.74 / -1.43%Today’s Change | 41.23 Today|||52-Week Range 52.83 | +10.61% Year-to-Date |
| Novo to Advance Egina Gold Project by Way of US $30 Million Farmin & Joint Venture Wi... Jun 07 / GlobeNewswirePNW - Paid Partner Content | Novo Egina Gold Project Update May 21 / GlobeNewswirePNW - Paid Partner Content |
| Karratha Gold Project Update??Completion of Mineralization Report and Outline of Futur... May 28 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 51.70 |
| Today’s open | 51.26 |
| Day’s range | 50.90 - 51.59 |
| Volume | 1,230,516 |
| Average volume (3 months) | 1,340,285 |
| Market cap | $89.2B |
| Earnings growth (last year) | +8.07% |
| Earnings growth (this year) | +0.13% |
| Earnings growth (next 5 years) | +8.90% |
| Revenue growth (last year) | +4.51% |
| P/E ratio | 21.4 |
| Price/Sales | 6.31 |
| Price/Book | 14.88 |
| Today’s change | Today’s % change | |
|---|---|---|
| GSKGlaxoSmithKline | -0.01 | -0.02% |
| AZNAstraZeneca | -0.24 | -0.60% |
| SNYSanofi | -0.21 | -0.49% |
| BMYBristol-Myers Squibb | +0.23 | +0.49% |
| Next reporting date | August 9, 2019 |
| EPS forecast (this quarter) | $0.61 |
| Annual revenue (last year) | $17.7B |
| Annual profit (last year) | $6.1B |
| Net profit margin | 34.54% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President & Chief Executive Officer Lars Fruergaard Jørgensen |
Executive Vice President- International Operations Maziar Mike Doustdar |
Corporate headquarters Bagsværd, Capital Region |
